Holding the Inflammatory System in Check: TLRs and Their Targeted Therapy in Asthma

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Dong, Zhiyong ^a   Xiong, Lingxin ^a   Zhang, Weijie ^b   Gibson, Peter G ^c   Wang, Ting ^a   Lu, Yanjiao ^a   Wang, Guoqiang ^a   Li, Hui ^b   Wang, Fang ^a  

^a JILIN UNIVERSITY   (China)

^b Jilin Tumor Hospital   (China)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; PATHOGEN ASSOCIATED MOLECULAR PATTERN;

ADAPTIVE IMMUNITY; ASTHMA; COUGHING; DENDRITIC CELL; DYSPNEA; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROBLAST; GENETIC POLYMORPHISM; HUMAN; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; VIRAL RESPIRATORY TRACT INFECTION; WHEEZING; ANIMAL; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ASTHMA; HUMANS; INFLAMMATION; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84971254633     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/2180417     Document Type: Review

References (76)

1. O. Takeuchi and S. Akira, "Pattern recognition receptors and inflammation, " Cell, vol. 140, no. 6, pp. 805-820, 2010.
2. R. Medzhitov, "Origin and physiological roles of inflammation, " Nature, vol. 454, no. 7203, pp. 428-435, 2008.
3. K. F. Chung, "Targeting the interleukin pathway in the treatment of asthma, " The Lancet, vol. 386, no. 9998, pp. 1086-1096, 2015.
4. S. Accordini, A. G. Corsico, M. Braggion et al., "The cost of persistent asthma in Europe: An international population-based study in adults, " International Archives of Allergy and Applied Immunology, vol. 160, no. 1, pp. 93-101, 2013.
5. S. Phipps, C. E. Lam, P. S. Foster, and K. I. Matthaei, "The contribution of toll-like receptors to the pathogenesis of asthma, " Immunology and Cell Biology, vol. 85, no. 6, pp. 463-470, 2007.
6. S. Goulopoulou, C. G. McCarthy, and R. C. Webb, "Toll-like receptors in the vascular system: sensing the dangers within, " Pharmacological Reviews, vol. 68, no. 1, pp. 142-167, 2016.
7. J. Jang, H. W. Shin, J. M. Lee, H. Lee, E. Kim, and S. H. Park, "An overviewof pathogen recognition receptors for innate immunity in dental pulp, "Mediators of Inflammation, vol. 2015, Article ID 794143, 12 pages, 2015.
8. L. Zuo, K. Lucas, C. A. Fortuna, C. Chuang, and T. M. Best, "Molecular regulation of toll-like receptors in asthma and COPD, " Frontiers in Physiology, vol. 6, article 312, 2015.
9. V. Piras and K. Selvarajoo, "BeyondMyD88 and TRIF pathways in Toll-like receptor signaling, " Frontiers in Immunology, vol. 5, article 70, 2014.
10. K. B. Narayanan and H. H. Park, "Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways, " Apoptosis, vol. 20, no. 2, pp. 196-209, 2015.
11. J. H. Lee, L. C. Wang, H. H. Yu, Y. T. Lin, Y. H. Yang, and B. L. Chiang, "Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma, " Mediators of Inflammation, vol. 2010, Article ID 567351, 7 pages, 2010.
12. T. Kawai, O. Adachi, T. Ogawa, K. Takeda, and S. Akira, "Unresponsiveness of MyD88-deficient mice to endotoxin, " Immunity, vol. 11, no. 1, pp. 115-122, 1999.
13. O. Takeuchi, K. Takeda, K. Hoshino, O. Adachi, T. Ogawa, and S. Akira, "Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades, " International Immunology, vol. 12, no. 1, pp. 113-117, 2000.
14. H. Häcker, R. M. Vabulas, O. Takeuchi, K. Hoshino, S. Akira, and H. Wagner, "Immune cell activation by bacterialCpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6, " The Journal of Experimental Medicine, vol. 192, no. 4, pp. 595-600, 2000.
15. F. Hayashi, K. D. Smith, A. Ozinsky et al., "The innate immune response to bacterial flagellin is mediated by Toll-like receptor-5, " Nature, vol. 410, no. 6832, pp. 1099-1103, 2001.
16. H. Hemmi, T. Kaisho, O. Takeuchi et al., "Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway, " Nature Immunology, vol. 3, no. 2, pp. 196-200, 2002.
17. M. Yamamoto, S. Sato, H. Hemmiet al., "Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway, " Science, vol. 301, no. 5633, pp. 640-643, 2003.
18. K. Hoebe, X. Du, P. Georgel et al., "Identification of Lps2 as a key transducer ofMyD88-independent TIR signalling, " Nature, vol. 424, no. 6950, pp. 743-748, 2003.
19. Global Initiative for Asthma, "GINA report, Global Stragety for Asthma Management and Prevention, " Documents/Resources, GINA, April 2015, http://ginasthma. org/wp-content/uploads/ 2016/01/GINA Report 2015 Aug11-1. pdf.
20. F. Wang, X. Y. He, K. J. Baines et al., "Different inflammatory phenotypes in adults and childrenwith acute asthma, " European Respiratory Journal, vol. 38, no. 3, pp. 567-574, 2011.
21. A. Agusti, E. Bel, M. Thomas et al., "Treatable traits: Toward precision medicine of chronic airway diseases, " European Respiratory Journal, vol. 47, no. 2, pp. 410-419, 2016.
22. M. W. Pijnenburg and S. Szefler, "Personalized medicine in children with asthma, " Paediatric Respiratory Reviews, vol. 16, no. 2, pp. 101-107, 2015.
23. K. M. Kew and K. Dahri, "Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma, " Cochrane Database of Systematic Reviews, no. 1, Article IDCD011721, 2016.
24. J. B. Bice, E. Leechawengwongs, and A. Montanaro, "Biologic targeted therapy in allergic asthma, " Annals of Allergy, Asthma and Immunology, vol. 112, no. 2, pp. 108-115, 2014.
25. J. L. Simpson, T. V. Grissell, J. Douwes, R. J. Scott, M. J. Boyle, and P. G. Gibson, "Innate immune activation in neutrophilic asthma and bronchiectasis, " Thorax, vol. 62, no. 3, pp. 211-218, 2007.
26. A.-K. Ekman, M. Adner, and L.-O. Cardell, "Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle, " European Journal of Pharmacology, vol. 652, no. 1-3, pp. 145-151, 2011.
27. I. Ioannidis, F. Ye, B. McNally, M. Willette, and E. Flaño, "Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells, " Journal of Virology, vol. 87, no. 6, pp. 3261-3270, 2013.
28. M. G. Drake, E. H. Kaufman, A. D. Fryer, and D. B. Jacoby, "The therapeutic potential of Toll-like receptor 7 stimulation in asthma, " Inflammation & Allergy-Drug Targets, vol. 11, no. 6, pp. 484-491, 2012.
29. S. T. Holgate, G. Roberts, H. S. Arshad, P. H. Howarth, and D. E. Davies, "The role of the airway epithelium and its interactionwith environmental factors in asthma pathogenesis, " Proceedings of the American Thoracic Society, vol. 6, no. 8, pp. 655-659, 2009.
30. L. Hatchwell, A. Collison, J. Girkin et al., "Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia, " Thorax, vol. 70, no. 9, pp. 854-861, 2015.
31. M. J. Duechs, C. Hahn, E. Benediktus et al., "TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways, " Pulmonary Pharmacology andTherapeutics, vol. 24, no. 2, pp. 203-214, 2011.
32. L. Meng, X. He, W. Zhu et al., "TLR3 and TLR7 modulate IgE production in antigen induced pulmonary inflammation via influencing IL-4 expression in immune organs, " PLoS ONE, vol. 6, no. 2, Article ID e17252, 2011.
33. B. Frotscher, K. Anton, and M. Worm, "Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors, " Journal of Investigative Dermatology, vol. 119, no. 5, pp. 1059-1064, 2002.
34. E. Shen, L. Lu, and C. Wu, "TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes, " Scandinavian Journal of Immunology, vol. 67, no. 6, pp. 560-568, 2008.
35. F. Brugnolo, S. Sampognaro, F. Liotta et al., "The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ T2 lymphocytes intoIFN-producing cells, " Journal of Allergy and Clinical Immunology, vol. 111, no. 2, pp. 380-388, 2003.
36. M. Wills-Karp, J. Luyimbazi, X. Xuet al., "Interleukin-13: central mediator of allergic asthma, " Science, vol. 282, no. 5397, pp. 2258-2261, 1998.
37. F. Grela, A. Aumeunier, E. Bardel et al., "The TLR7 agonist R848 alleviates allergic inflammation by targeting invariantNKTcells to produce IFN, "TheJournal of Immunology, vol. 186, no. 1, pp. 284-290, 2011.
38. Q. Du, L.-F. Zhou, Z. Chen, X.-Y. Gu, M. Huang, and K.-S. Yin, "Imiquimod, a toll-like receptor 7 ligand, inhibits airway remodelling in amurine model of chronic asthma, " Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 1, pp. 43-48, 2009.
39. P. Camateros, M. Tamaoka, M. Hassan et al., "Chronic asthmainduced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463, " American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 12, pp. 1241-1249, 2007.
40. S. W. Lee, D. R. Kim, T. J. Kim et al., "The association of downregulated toll-like receptor 4 expression with airflow limitation and emphysema in smokers, " Respiratory Research, vol. 13, article106, 2012.
41. M. Werner, R. Topp, K. Wimmer et al., "TLR4 gene variants modify endotoxin effects on asthma, " Journal of Allergy and Clinical Immunology, vol. 112, no. 2, pp. 323-330, 2003.
42. Q. Zhang, F. H. Qian, L. F. Zhou et al., "Polymorphisms in toll-like receptor 4 gene are associated with asthma severity but not susceptibility in a Chinese Han population, " Journal of Investigational Allergology and Clinical Immunology, vol. 21, no. 5, pp. 370-377, 2011.
43. K. Tizaoui, W. Kaabachi, K. Hamzaoui, and A. Hamzaoui, "Association of single nucleotide polymorphisms in Toll-like receptor genes with asthma risk: A systematic review and metaanalysis, " Allergy, Asthma & Immunology Research, vol. 7, no. 2, pp. 130-140, 2015.
44. E. M. M. Klaassen, B. E. J. T. Thönissen, G. van Eys, E. Dompeling, and Q. Jöbsis, "A systematic review of CD14 and toll-like receptors in relation to asthma in Caucasian children, " Allergy, Asthma and Clinical Immunology, vol. 9, article 10, 2013.
45. F. H. Qian, Q. Zhang, L. F. Zhou, G. F. Jin, J. L. Bai, and K. S. Yin, "Polymorphisms in the toll-like receptor2 subfamily and risk of asthma: A case-control analysis in a Chinese population, " Journal of Investigational Allergology and Clinical Immunology, vol. 20, no. 4, pp. 340-346, 2010.
46. A. Heinzmann, M. Brugger, S. Bierbaum, B. Mailaparambil, M. V. Kopp, and K. Strauch, "Joint influences of Acidic-Mammalian-Chitinase with Interleukin-4 and Toll-like receptor-10 with Interleukin-13 in the genetics of asthma, " Pediatric Allergy and Immunology, vol. 21, no. 4, part 2, pp. e679-e686, 2010.
47. R. Lazarus, W. T. Klimecki, B. A. Raby et al., "Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U. S. ethnic groups and exploratory case-control disease association studies, " Genomics, vol. 81, no. 1, pp. 85-91, 2003.
48. M. S. D. Kormann, M. Depner, D. Hartl et al., "Toll-like receptor heterodimer variants protect from childhood asthma, " Journal of Allergy and Clinical Immunology, vol. 122, no. 1, pp. 86-e8, 2008.
49. T. V. Grissell, H. Powell, D. R. Shafrenet al., "Interleukin-10gene expression in acute virus-induced asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 4, pp. 433-439, 2005.
50. P. A. B. Wark, S. L. Johnston, I. Moric, J. L. Simpson, M. J. Hensley, and P. G. Gibson, "Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma, " European Respiratory Journal, vol. 19, no. 1, pp. 68-75, 2002.
51. H. Rupani, R. T. Martinez-Nunez, P. Dennison et al., "Toll-like receptor 7 is reduced in severe asthma and linked to altered microRNA profile, " American Journal of Respiratoryand Critical Care Medicine, 2016.
52. M. Contoli, S. D. Message, V. Laza-Stanca et al., "Role of deficient type III interferon production in asthma exacerbations, " Nature Medicine, vol. 12, no. 9, pp. 1023-1026, 2006.
53. A. Sykes, M. R. Edwards, J. MacIntyre et al., "Rhinovirus 16-induced IFN and IFN are deficient in bronchoalveolar lavage cells in asthmatic patients, " Journal of Allergy and Clinical Immunology, vol. 129, no. 6, pp. 1506-1514, 2012.
54. A. L. Pritchard, O. J. White, J. G. Burel, M. L. Carroll, S. Phipps, and J. W. Upham, "Asthma is associated with multiple alterations in anti-viral innate signalling pathways, " PLoS ONE, vol. 9, no. 9, Article ID e106501, 2014.
55. M. Matsumoto, H. Oshiumi, and T. Seya, "Antiviral responses induced by the TLR3 pathway, " Reviews inMedical Virology, vol. 21, no. 2, pp. 67-77, 2011.
56. K. S. Parsons, A. C. Hsu, and P. A. B. Wark, "TLR3 andMDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection, " Clinical and Experimental Allergy, vol. 44, no. 1, pp. 91-101, 2014.
57. R. H. Xu, E. B. Wong, D. Rubio et al., "Sequential activation of two pathogen-sensing pathways required for Type I interferon expression and resistance to an acute DNA virus infection, " Immunity, vol. 43, no. 6, pp. 1148-1159, 2015.
58. D. Tworek, S. G. Smith, B. M. Salter et al., "Interleukin 25 receptor expression on airwaydendritic cells after allergen challenge in asthmatic subjects, " American Journal of Respiratory and Critical Care Medicine, 2015.
59. M. J. Duechs, C. Tilp, C. Tomsic, F. Gantner, and K. J. Erb, "Development of a novel severe triple allergen asthma model in mice which is resistant to dexamethasone and partially resistant to TLR7 and TLR9 agonist treatment, " PLoS ONE, vol. 9, no. 3, Article ID e91223, 2014.
60. J. N. Kline, T. J. Waldschmidt, T. R. Businga et al., "Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma, "The Journal of Immunology, vol. 160, no. 6, pp. 2555-2559, 1998.
61. A. Lhrmann, T. Tschernig, H. von der Leyen, M. Hecker, R. Pabst, and A. H. Wagner, "Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model, " Experimental Lung Research, vol. 36, no. 2, pp. 85-93, 2010.
62. V. V. Jain, K. Kitagaki, T. Businga et al., "CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma, " Journal of AllergyandClinical Immunology, vol. 110, no. 6, pp. 867-872, 2002.
63. S. Y. Lee, J. Y. Cho, M. Miller et al., "Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice, " Journal of Allergy and Clinical Immunology, vol. 117, no. 3, pp. 597-603, 2006.
64. D.-J. Chiang, Y.-L. Ye, W.-L. Chen, Y.-L. Lee, N.-Y. Hsu, and B.-L. Chiang, "Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation, " American Journal of Respiratory and Critical CareMedicine, vol. 168, no. 5, pp. 575-580, 2003.
65. S. Ashino, D. Wakita, Y. Zhang, K. Chamoto, H. Kitamura, and T. Nishimura, "CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung, " International Immunology, vol. 20, no. 2, pp. 259-266, 2008.
66. A. Fedulov, E. Silverman, Y. Xiang, A. Leme, and L. Kobzik, "Immunostimulatory CpG oligonucleotides abrogate allergic susceptibility in a murine model of maternal asthma transmission, " The Journal of Immunology, vol. 175, no. 7, pp. 4292-4300, 2005.
67. Z. Aryan, S. T. Holgate, D. Radzioch, and N. Rezaei, "A new era of targeting the ancient gatekeepers of the immune system: Tolllike agonists in the treatment of allergic rhinitis and asthma, " International Archives of Allergy and Immunology, vol. 164, no. 1, pp. 46-63, 2014.
68. C. M. Trujillo-Vargas, J. R. Ramirez-Pineda, A. Palmetshofer et al., "Mice vaccinated with allergen-pulsed myeloid dendritic cells are not protected from developing allergen-induced Th2 responses, " International Archives of Allergy and Immunology, vol. 137, no. 3, pp. 219-228, 2005.
69. S. Kapoor, L. Geng, A. Feldman, and H. Jyonouchi, "Characterization of severe asthma (SA) in children of inner-city of Newark: Altered responses to recall antigens and a panel of agonists of Toll-like receptors (TLR), " Journal of Allergy and Clinical Immunology, vol. 127, articleAB61, 2011.
70. M. Tamm, D. H. Richards, B. Beghé, and L. Fabbri, "Inhaled corticosteroid and long-acting 2-agonist pharmacological profiles: effective asthma therapy in practice, " RespiratoryMedicine, vol. 106, no. 1, pp. S9-S19, 2012.
71. C. Xirakia, O. Koltsida, A. Stavropoulos et al., "Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 11, pp. 1207-1216, 2010.
72. J. Moisan, P. Camateros, T. Thuraisingam et al., "TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway, " American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 290, no. 5, pp. L987-L995, 2006.
73. D. Quarcoo, S. Weixler, R. A. Joachim et al., "Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice, " Clinical and Experimental Allergy, vol. 34, no. 8, pp. 1314-1320, 2004.
74. K. Ito, K. F. Chung, and I. M. Adcock, "Update on glucocorticoid action and resistance, " Journal of Allergy and Clinical Immunology, vol. 117, no. 3, pp. 522-543, 2006.
75. E. Chun, S.-H. Lee, S.-Y. Lee et al., "Toll-like receptor expression on peripheral blood mononuclear cells in asthmatics; implications for asthma management, " Journal of Clinical Immunology, vol. 30, no. 3, pp. 459-464, 2010.
76. E. Pace, C. Di Sano, M. Ferraro et al., "Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics, " Pulmonary Pharmacology andTherapeutics, vol. 32, pp. 93-100, 2015.